sulanemadlin

Sulanemadlin is an investigational stapled peptide drug developed for the treatment of cancer, notably myelodysplastic syndrome and acute myeloid leukemia. It is the first cell-permeating, stabilized α-helical peptide to enter clinical trials. Sulanemadlin mimics the N-terminal domain of p53, a tumor suppressor protein, and binds with high affinity to both MDM2 and MDMX (also known as MDM4), which are endogenous inhibitors of p53. By inhibiting these proteins, sulanemadlin activates p53 signaling in cells with wild-type TP53 genotype, leading to cell cycle arrest or apoptosis in cancer cells. At lower doses, it can transiently arrest the cell cycle in healthy tissues to protect them from chemotherapy-induced damage without protecting TP53-mutant cancer cells[1][5][6].

Other names

N-acetyl-l-leucyl-l-threonyl-l-phenylalanyl-cyclo(d-r8-l-glutamyl-ltyrosyl-ltryptophanyl-l-alanyl-l-glutaminyl-l-leucyl-l-s5)-l-alanyl-lalanyl-l-alanyl-l-alanyl-lalanyl-d-alanylamide6BGF28R54M1451199-98-6